Latest available resultsQuarter ended March 31, 202610-Q · April 29, 2026
Filed with the SECABBOTT LABORATORIES
ABTPharma & biotech
Results announcedJuly 16, 2026▲ +1.4%
Detailed filing pendingNext reportOctober 13, 2026pre-market · Analyst forecast 1.435 $/share
Revenue
$11.16B
▲ +7.8% vs prior year% YoY
Net income
$1.08B
▼ -18.7% vs prior year% YoY
EPS
0.61$
▼ -19.7% vs prior year% YoY
Net margin
9.6%
▼ -3.1 percentage points vs prior year pp YoY
Revenue▲ +7.8 %
Margins (% of revenue)GrossOperatingNet
Net income▼ -18.7 %
EPS▼ -19.7 %
View financial tableQuarter ended March 31, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $11.16B | |
| Gross profit | $6.27B | 56.2 % |
| Operating income | $1.34B | 12.0 % |
| Net income | $1.08B | 9.6 % |
| R&D | $767.00M | 6.9 % |
| EPS (diluted) | 0.61 $ | |
| Balance sheet | ||
| Assets | $110.43B | |
| Liabilities | $57.73B | |
| Equity | $52.70B | |
| Cash | $6.80B | |
| Capital | ||
| Shares outstanding | 1.74B | as of 2026-03-31 |
| Public float | — | |